Since Meiji started its sales of Meiact within Japan in 1994, it is used as a cephem antibiotic to treat a wide range of infectious diseases. Meiact has already been approved in 27 countries and regions and is used around the world.
PT. Meiji has sold Meiact tablets in Indonesia since 2004. By adding Meiact Fine Granules, we believe we can make further contributions to the treatment of local pediatric infectious diseases. In the future, PT. Meiji will conduct promotional activities mainly at PT Meiji's 21 sales offices in Indonesia.
Through PT. Meiji, Meiji will contribute to the treatment of infectious diseases in Indonesia as a leading company in the treatment of infectious diseases in Asia.
About Meiji Seika Pharma Co., Ltd
Address: Chuo-ku, Tokyo Japan
President Director: Daikichiro Kobayashi
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/
About PT. Meiji Indonesian Pharmaceutical Industries
Established: 1974
Address: Jalan Prof. Dr. Soepomo No. 40, Tebet, Jakarta Selatan, 12870 Indonesia
President Director: Masanobu Sato
Employees: 799, as of March, 2019
Parent Company: Meiji Seika Pharma Co., Ltd.
Scope of Business: Manufacture, sales, and export of medical materials
https://meiji.co.id/id
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
Contacts
PT. Meiji Indonesian Pharmaceutical Industries
Heddy Triyana Putra (Mr.), General Affairs/Legal Department Head
Telephone: +62-21-21383388
Source: Meiji Seika Pharma
Reporter: PR Wire
Editor: PR Wire
Copyright © ANTARA 2019
